This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Social Bookmarking   What's this?

Peter A. Campochiaro, MD; Jennifer I. Lim, MD; Aminoglycoside Toxicity Study Group

Arch Ophthalmol. 1994;112(1):48-53.

Abstract
Objective and Methods
Intravitreous aminoglycosides are widely used for the treatment and prophylaxis of endophthalmitis. Because the toxicity of 0.4 mg of gentamicin sulfate is well documented, many surgeons now use amikacin sulfate or low-dose gentamicin to reduce the risk of macular infarction. A survey of retinal specialists has suggested that amikacin or low-dose gentamicin can also cause macular toxic side effects. To further investigate this issue, the critical details of the case histories, findings, and course of 13 patients who received intravitreous injections of 0.2 to 0.4 mg of amikacin sulfate or 0.1 to 0.2 mg of gentamicin sulfate for prophylaxis or treatment of endophthalmitis are summarized. For several patients, complete case histories and a fluorescein angiogram are provided.

Results
These cases suggest that amikacin and low-dose gentamicin, similar to gentamicin sulfate at a dose of 0.4 mg, can cause macular infarction. The causative dose cannot be ascertained in any of the cases, but doses were prepared by hospital pharmacists using typewritten protocols, a practice that helps to prevent dilution errors. Several of these cases differ from previously reported cases of aminoglycoside toxicity in that the involvement of the macula was quite discrete. Most of the patients suffered severe visual loss, but two patients, in whom most of the nonperfusion was adjacent to the macula and in whom some of the perifoveal capillaries were spared, recovered 20/50 visual acuity.

Conclusions
These cases emphasize the potential hazards of the intravitreous use of aminoglycosides. A toxic reaction can occur even when injection of low doses is intended and precautions are made to avoid dilution errors. A localized increase in concentration in dependent areas of the retina may play a role in aminoglycoside toxicity. If some of the perifoveal capillaries are spared, retention of some central vision is possible. Consideration should be given to substituting ceftazidime for aminoglycosides for the treatment and prophylaxis of endophthalmitis.

Author Affiliations
From The Wilmer Ophthalmological Institute, The Johns Hopkins Hospital, Baltimore, Md (Dr Campochiaro), and The Emory Clinic, Atlanta, Ga (Dr Lim).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Prophylaxis for Posttraumatic Endophthalmitis
Rohan W. Essex, Ecosse Lamoureux, Patrick G. P. Charles, and Penny Allen
Arch Ophthalmol. 2008;126(5):742-743.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prophylaxis for Posttraumatic Endophthalmitis
Essex et al.
Arch Ophthalmol 2008;126:742-743.
FULL TEXT  

Toward Improving Therapeutic Regimens for Bacillus Endophthalmitis
Wiskur et al.
IOVS 2008;49:1480-1487.
ABSTRACT | FULL TEXT  

An in vitro study on the compatibility and precipitation of a combination of ciprofloxacin and vancomycin in human vitreous
Hui et al.
Br J Ophthalmol 2004;88:218-222.
ABSTRACT | FULL TEXT  

An In Vitro Study of Ceftazidime and Vancomycin Concentrations in Various Fluid Media: Implications for Use in Treating Endophthalmitis
Kwok et al.
IOVS 2002;43:1182-1188.
ABSTRACT | FULL TEXT  

Bacterial Endophthalmitis: Epidemiology, Therapeutics, and Bacterium-Host Interactions
Callegan et al.
Clin. Microbiol. Rev. 2002;15:111-124.
ABSTRACT | FULL TEXT  

Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis
Gan et al.
Br J Ophthalmol 2001;85:1289-1293.
ABSTRACT | FULL TEXT  

Vancomycin and ceftazidime incompatibility upon intravitreal injection
LIFSHITZ et al.
Br J Ophthalmol 2000;84:117a-117.
FULL TEXT  

Amikacin retinal toxicity
JACKSON and WILLIAMSON
Br J Ophthalmol 1999;83:1194f-1194.
FULL TEXT  

Current approach to postoperative endophthalmitis
SUNARIC-MEGEVAND and POURNARAS
Br J Ophthalmol 1997;81:1006-1015.
FULL TEXT  

Assessment of a standard treatment protocol on visual outcome following presumed bacterial endophthalmitis
Okhravi et al.
Br J Ophthalmol 1997;81:719-725.
ABSTRACT | FULL TEXT  

Comparative Intravitreal Antibiotic Therapy for Experimental Enterococcus faecalis Endophthalmitis
Choi et al.
Arch Ophthalmol 1996;114:61-65.
ABSTRACT  

Aminoglycoside Macular Infarction in Association With Gentamicin-Soaked Collagen Corneal Shield
Kanter and Brucker
Arch Ophthalmol 1995;113:1359-1360.
ABSTRACT  

Controversies in Endophthalmitis Prevention: The Risk for Emerging Resistance to Vancomycin
Alfonso and Flynn
Arch Ophthalmol 1995;113:1369-1370.
ABSTRACT  

Aminoglycoside Toxicity in the Treatment of Endophthalmitis
Grizzard
Arch Ophthalmol 1995;113:262-263.
ABSTRACT